Association Among Resistin, Adenylate Cyclase-associated Protein 1 and High-density Lipoprotein Cholesterol in Patients with Colorectal Cancer: a Multi-marker Approach, As a Hallmark of Innovative Predictive, Preventive, and Personalized Medicine

Overview

Journal EPMA J

Date 2019 Aug 30

PMID 31462946

Citations 9

Authors

Marija Mihajlovic

Ana Ninic

Miron Sopic

Milica Miljkovic

Aleksandra Stefanovic

Jelena Vekic

Vesna Spasojevic-Kalimanovska

Dejan Zeljkovic

Bratislav Trifunovic

Zeljka Stjepanovic

Aleksandra Zeljkovic

Affiliations

Soon will be listed here.

Abstract

Background: Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.

Methods: Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin's concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism.

Results: Plasma resistin and CAP-1 mRNA levels were higher in CRC patients ( < 0.001 and < 0.05, respectively), while resistin mRNA levels were lower ( < 0.001). Negative association existed among plasma resistin and HDL-C concentrations ( = - 0.280; < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers.

Conclusions: Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin's secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.

Citing Articles

Decoding Resistin Gene Polymorphisms: Implications for Lung Cancer Risk and Clinical Outcomes of Platinum-Based Chemotherapy.

Gong W, Huang D, Zhou T, Zhu X, Huang Y, Lv Y Biomedicines. 2025; 13(2).

PMID: 40002704 PMC: 11852191. DOI: 10.3390/biomedicines13020291.

Relationships between nutritional status and serum adipokine levels with chemotherapy efficacy in late-stage colorectal cancer patients.

Zhang W, Wang S Int J Colorectal Dis. 2025; 40(1):25.

PMID: 39873770 PMC: 11775029. DOI: 10.1007/s00384-024-04791-9.

An Updated Review of Resistin and Colorectal Cancer.

Rompou A, Bletsa G, Tsakogiannis D, Theocharis S, Vassiliu P, Danias N Cureus. 2024; 16(7):e65403.

PMID: 39184804 PMC: 11344879. DOI: 10.7759/cureus.65403.

The Modulation of Adipokines, Adipomyokines, and Sleep Disorders on Carcinogenesis.

Brzecka A, Martynowicz H, Daroszewski C, Majchrzak M, Ejma M, Misiuk-Hojlo M J Clin Med. 2023; 12(7).

PMID: 37048738 PMC: 10094938. DOI: 10.3390/jcm12072655.

Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings.

Mihajlovic M, Ninic A, Ostojic M, Sopic M, Stefanovic A, Vekic J Int J Environ Res Public Health. 2022; 19(22).

PMID: 36429712 PMC: 9691131. DOI: 10.3390/ijerph192214995.

References

Kaser S, Kaser A, Sandhofer A, Ebenbichler C, Tilg H, Patsch J . Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003; 309(2):286-90. DOI: 10.1016/j.bbrc.2003.07.003. View

Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H . The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004; 75(4):678-86. PMC: 1182055. DOI: 10.1086/424761. View

Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T . Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007; 19(12):1070-4. DOI: 10.1097/MEG.0b013e3282f16251. View

Nystrom M, Mutanen M . Diet and epigenetics in colon cancer. World J Gastroenterol. 2009; 15(3):257-63. PMC: 2653321. DOI: 10.3748/wjg.15.257. View

Kunnari A, Savolainen E, Ukkola O, Kesaniemi Y, Jokela M . The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept. 2009; 157(1-3):57-63. DOI: 10.1016/j.regpep.2009.05.002. View

Tarkowski A, Bjersing J, Shestakov A, Bokarewa M . Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2009; 14(6B):1419-31. PMC: 3829009. DOI: 10.1111/j.1582-4934.2009.00899.x. View

Osawa H, Tabara Y, Ohashi J, Kawamura R, Onuma H, Makino H . Is rs34861192 or rs1862513 a more promising variant for determining plasma resistin in an aged Japanese population?. Diabetologia. 2010; 53(4):795-7. PMC: 2830588. DOI: 10.1007/s00125-010-1665-4. View

Nakajima T, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S . Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010; 101(5):1286-91. PMC: 11159666. DOI: 10.1111/j.1349-7006.2010.01518.x. View

Schwartz D, Lazar M . Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011; 22(7):259-65. PMC: 3130099. DOI: 10.1016/j.tem.2011.03.005. View

10.

Danese E, Montagnana M, Minicozzi A, Bonafini S, Ruzzenente O, Gelati M . The role of resistin in colorectal cancer. Clin Chim Acta. 2012; 413(7-8):760-4. DOI: 10.1016/j.cca.2012.01.019. View

11.

Golubnitschaja O, Costigliola V . General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012; 3(1):14. PMC: 3485619. DOI: 10.1186/1878-5085-3-14. View

12.

Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y . Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013; 8(1):e53916. PMC: 3547959. DOI: 10.1371/journal.pone.0053916. View

13.

Ono S . The role of cyclase-associated protein in regulating actin filament dynamics - more than a monomer-sequestration factor. J Cell Sci. 2013; 126(Pt 15):3249-58. PMC: 3730240. DOI: 10.1242/jcs.128231. View

14.

Geyikli I, Keskin M, Kor Y, Akan M . Increased resistin serum concentrations in patientswith type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013; 5(3):189-93. PMC: 3814534. DOI: 10.4274/Jcrpe.1072. View

15.

Dalamaga M . Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med. 2013; 8(1):107-18. DOI: 10.2217/bmm.13.99. View

16.

Ghaemmaghami S, Mohaddes S, Hedayati M, Gorgian Mohammadi M, Dehbashi G . Resistin and Visfatin Expression in HCT-116 Colorectal Cancer Cell Line. Int J Mol Cell Med. 2014; 2(3):143-50. PMC: 3920537. View

17.

Lee S, Lee H, Kwon Y, Lee S, Cho Y, Kim J . Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab. 2014; 19(3):484-97. PMC: 3969988. DOI: 10.1016/j.cmet.2014.01.013. View

18.

Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F . Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol. 2014; 20(18):5177-90. PMC: 4017033. DOI: 10.3748/wjg.v20.i18.5177. View

19.

Hsieh Y, Shen C, Huang W, Chin C, Kuo Y, Hsieh M . Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells. J Biomed Sci. 2014; 21:59. PMC: 4089564. DOI: 10.1186/1423-0127-21-59. View

20.

Asgary S, SamsamShariat S, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N . Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr. 2014; 9(4):266-70. DOI: 10.1016/j.dsx.2014.09.007. View